Screener / SEC EDGAR /CIK 0001649904 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Rhythm Pharmaceuticals, Inc. RYTM

Compare with peers Embed
Planned sales, announced before they happen

9 trading plans running, 15 Form 144 notices for $46.2M

10-Q, 10-K and Form 144
Plans running now 9 Alastair Garfield, Christophe Jean, David McGirr, Jennifer Lee, Hunter Smith, Yann Mazzabraud, Joseph Shulman, Pamela Cramer
Plans adopted 22 reported since May 2, 2023 Form 144 notices 15 $46.2M the sellers expected to sell

What RYTM's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Dec 15, 2025 to Feb 1, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
David Meeker
Chief Executive Officer
Ended 10b5-1 plan Sep 18, 2026 10-Q Nov 3, 2026
What the company wrote
On September 18, 2026 , David Meeker, the Company's Chief Executive Officer, terminated a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, which was previously adopted on June 15, 2026 and provided for the sale of up to 300,000 shares of the Company's common stock until March 15, 2027.
Alastair Garfield
Chief Scientific Officer
Adopted 10b5-1 plan Sep 9, 2026 10-Q Nov 3, 2026
What the company wrote
On September 9, 2026, Alastair Garfield, the Company's Chief Scientific Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 100% of the shares of our common stock issued to Dr. Garfield upon the settlement of outstanding restricted stock units, less the number of shares surrendered to the issuer or sold to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until February 1, 2028.
Christophe Jean
Director
Adopted 10b5-1 plan Aug 18, 2026 10-Q Nov 3, 2026
What the company wrote
On August 18, 2026, Christophe Jean, the Company's Director, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 10,000 shares of the Company's common stock until July 17, 2027.
David McGirr
Director
Adopted 10b5-1 plan Aug 6, 2026 10-Q Nov 3, 2026
What the company wrote
On August 6, 2026, David McGirr, the Company's Director, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 21,810 shares of the Company's common stock until February 7, 2027.
Lynn Tetrault
member of the Company’s Board of Directors
Ended 10b5-1 plan Jun 24, 2026 10-Q Aug 4, 2026
What the company wrote
On June 24, 2026, Lynn Tetrault, a member of the Company’s Board of Directors, terminated a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, which was previously adopted on December 15, 2025 and provided for the sale of up to 55,000 shares of the Company’s common stock until September 16, 2026.
David Meeker
Company's Chief Executive Officer
Adopted 10b5-1 plan Jun 15, 2026 10-Q Aug 4, 2026
What the company wrote
On June 15, 2026, David Meeker, the Company's Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 300,000 shares of the Company's common stock until March 15, 2027.
Alastair Garfield
Company's Chief Scientific Officer
Adopted 10b5-1 plan May 14, 2026 10-Q Aug 4, 2026
What the company wrote
On May 14, 2026, Alastair Garfield, the Company's Chief Scientific Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 7,763 shares of the Company's common stock until February 13, 2027.
Jennifer Lee
Company's Executive Vice President, Head of North America
Adopted 10b5-1 plan May 14, 2026 10-Q Aug 4, 2026
What the company wrote
On May 14, 2026, Jennifer Lee, the Company's Executive Vice President, Head of North America, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 76,201 shares of the Company's common stock as well as up to 100% of the shares of our common stock issued to Ms. Lee upon the settlement of outstanding restricted stock units, less the number of shares surrendered to the issuer or sold to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until March 1, 2027.
Hunter Smith
Company's Chief Financial Officer
Adopted 10b5-1 plan May 13, 2026 10-Q Aug 4, 2026
What the company wrote
On May 13, 2026, Hunter Smith, the Company's Chief Financial Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 62,774 shares of the Company's common stock as well as up to 100% of the shares of our common stock issued to Mr. Smith upon the settlement of outstanding restricted stock units, less the number of shares surrendered to the issuer or sold to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until May 12, 2027.
Yann Mazzabraud
Company's Executive Vice President, Head of International
Adopted 10b5-1 plan May 13, 2026 10-Q Aug 4, 2026
What the company wrote
On May 13, 2026, Yann Mazzabraud, the Company's Executive Vice President, Head of International, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 57,000 shares of the Company's common stock until August 15, 2027.
Jennifer Lee
Company's EVP, Head of North America
Adopted 10b5-1 plan Dec 15, 2025 10-K Feb 26, 2026
What the company wrote
On December 15, 2025, Jennifer Lee, the Company's EVP, Head of North America, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 62,459 shares of the Company's common stock until October 1, 2026.
Joseph Shulman
Company's Chief Technical Officer
Adopted 10b5-1 plan Dec 15, 2025 10-K Feb 26, 2026
What the company wrote
On December 15, 2025, Joseph Shulman, the Company's Chief Technical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 66,910 shares of the Company's common stock until March 12, 2027.
Lynn Tetrault
member of the Company's Board of Directors
Adopted 10b5-1 plan Dec 15, 2025 10-K Feb 26, 2026
What the company wrote
On December 15, 2025, Lynn Tetrault, a member of the Company's Board of Directors, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 55,000 shares of the Company's common stock until September 16, 2026.
Pamela Cramer
Company's Chief Human Resources Officer
Adopted 10b5-1 plan Dec 15, 2025 10-K Feb 26, 2026
What the company wrote
On December 15, 2025, Pamela Cramer, the Company's Chief Human Resources Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 52,617 shares of the Company's common stock until March 15, 2027.
Jennifer Kayden Lee
Company’s Executive Vice President, Head of North America
Adopted 10b5-1 plan Aug 8, 2025 10-Q Nov 4, 2025
What the company wrote
On August 8, 2025, Jennifer Kayden Lee, the Company’s Executive Vice President, Head of North America, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 62,459 shares of the Company’s common stock as well as up to 100% of the shares of our common stock issued upon the settlement of outstanding restricted stock units, less the number of shares traded to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until June 1, 2026.
Pamela Cramer
Company’s Chief Human Resources Officer
Adopted 10b5-1 plan Aug 7, 2025 10-Q Nov 4, 2025
What the company wrote
On August 7, 2025, Pamela Cramer, the Company’s Chief Human Resources Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 29,566 shares of the Company’s common stock until November 1, 2026.
Jennifer Good
board of directors
Ended 10b5-1 plan May 22, 2025 10-Q/A Aug 14, 2024
Pamela J. Cramer
Chief Human Resources Officer
Ended 10b5-1 plan May 15, 2025 10-Q/A Aug 14, 2024
Christopher German
Corporate Controller and Chief Accounting Officer
Adopted 10b5-1 plan Mar 11, 2025 10-Q May 7, 2025
What the company wrote
On March 11, 2025, Christopher German, the Company’s Corporate Controller and Chief Accounting Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 7,386 shares of the Company’s common stock until June 10, 2026.
David Meeker
Chairman, President, and Chief Executive Officer
Adopted 10b5-1 plan Mar 3, 2025 10-Q May 7, 2025
What the company wrote
On March 3, 2025, David Meeker, the Company’s Chairman, President, and Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 43,621 shares of the Company’s common stock until November 7, 2025.
David McGirr
board of directors
Adopted 10b5-1 plan Feb 28, 2025 10-Q May 7, 2025
What the company wrote
On February 28, 2025, David McGirr, a member of the Company’s board of directors, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 65,431 shares of the Company’s common stock until November 7, 2025.
Hunter Smith
Chief Financial Officer
Adopted 10b5-1 plan Feb 28, 2025 10-Q May 7, 2025
What the company wrote
On February 28, 2025, Hunter Smith, the Company’s Chief Financial Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 121,185 shares of the Company’s common stock until May 30, 2026.
Pamela Cramer
Chief Human Resources Officer
Adopted 10b5-1 plan Dec 16, 2024 10-K Feb 28, 2025
What the company wrote
On December 16, 2024, Pamela Cramer, the Company’s Chief Human Resources Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 50,394 shares of the Company’s common stock until March 17, 2026.
Yann Mazabraud
EVP, Head of International
Adopted 10b5-1 plan Dec 13, 2024 10-K Feb 28, 2025
What the company wrote
On December 13, 2024, Yann Mazabraud, the Company’s EVP, Head of International, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 99,495 shares of the Company’s common stock until November 11, 2025.
Lynn Tetrault
board of directors
Ended 10b5-1 plan Nov 28, 2024 10-Q/A Aug 14, 2024
Jennifer Kayden Lee
EVP, Head of North America
Adopted 10b5-1 plan Aug 8, 2024 10-Q Nov 6, 2024
What the company wrote
On August 8, 2024, Jennifer Kayden Lee, the Company’s EVP, Head of North America, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 71,050 shares of the Company’s common stock until September 1, 2025.
Jospeh Shulman
Chief Technical Officer
Adopted 10b5-1 plan Aug 8, 2024 10-Q Nov 6, 2024
What the company wrote
On August 8, 2024, Jospeh Shulman, the Company’s Chief Technical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 73,203 shares of the Company’s common stock until November 5, 2025.
Show the other 19 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 2, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Sep 14, 2026 David Meeker
Director, Officer
50,000 $5.2M
Aug 31, 2026 HUNTER SMITH
Officer
62,774 $6.7M
Aug 13, 2026 ALASTAIR GARFIELD
Officer
7,763 $913K
Aug 13, 2026 JOSEPH J SHULMAN
Officer
5,079 $597K
Aug 13, 2026 Jennifer Kayden Lee
Officer
75,834 $8.9M
Aug 12, 2026 YANN MAZABRAUD
Officer
57,000 $6.4M
Aug 11, 2026 PAMELA CRAMER
Officer
11,406 $1.3M
Aug 10, 2026 PAMELA CRAMER
Officer
3,520 $407K
Jun 22, 2026 LYNN TETRAULT
Director
37,000 $3.6M
Mar 4, 2026 CAMILLE L BEDROSIAN
Director
64,540 $5.8M
Mar 3, 2026 CAMILLE L BEDROSIAN
Director
35,460 $3.2M
Feb 5, 2026 HUNTER SMITH
Officer
18,406 $2.0M
Feb 4, 2026 HUNTER SMITH
Officer
3,247 $352K
Dec 11, 2025 PAMELA CRAMER
Officer
3,350 $351K
Nov 20, 2025 PAMELA CRAMER
Officer
3,350 $346K
Show the other 7 notices

From the Form 144 XML filed with the SEC, since Nov 20, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RYTM/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.